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In Duchenne muscular dystrophy (DMD) the absence
of dystrophin at the sarcolemma delocalizes and
downregulates nitric oxide synthase (nNOS); this
alters S-nitrosylation of HDAC2 and its chromatin
association. We show that the differential HDAC2
nitrosylation state in Duchenne versus wild-type
conditions deregulates the expression of a specific
subset of microRNA genes. Several circuitries
controlled by the identified microRNAs, such as the
one linking miR-1 to the G6PD enzyme and the redox
stateofcell, ormiR-29 toextracellularproteinsand the
fibrotic process, explain some of the DMD pathoge-
netic traits. We also show that, at variance with other
myomiRs, miR-206 escapes from the dystrophin-
nNOS control being produced in activated satellite
cells before dystrophin expression; in these cells, it
contributes to muscle regeneration through repres-
sion of the satellite specific factor, Pax7.Weconclude
that the pathway activated by dystrophin/nNOS
controls several important circuitries increasing the
robustness of the muscle differentiation program.INTRODUCTION
Duchenne muscular dystrophy (DMD) is an X-linked recessive
disorder caused by mutations in the dystrophin gene. Its pro-
duct, dystrophin (427 kDa), links the cytoskeleton to a complex
of proteins (dystrophin-associated protein complex, DAPC)
on the membrane of muscle fibers (Matsumura et al., 1994).
The principal role of DAPC is to connect intracellular actin micro-
filaments to the extracellular matrix determining a structural
stabilization of the sarcolemma (Ervasti and Sonnemann,
2008). The absence of dystrophin in DMD patients leads to
a dramatic decrease of the DAPC. As a consequence, muscle
fibers become more sensitive to mechanical damage, leadingCellto muscle degeneration, chronic inflammation, susceptibility to
oxidative stress, and increased fibrosis, all of which exacerbate
the dystrophic phenotype.
Over the past 20 years, the mdx mouse, carring a stop codon
inside exon 23 of the dystrophin gene, has been widely used as
animal model of DMD pathology. Moreover, it provides a conve-
nient system to test possible therapeutic interventions as well as
to select molecular markers that could be useful to monitor
disease progression and therapeutic outcomes.
It has been shown that most of the mutations in the dystrophin
gene can be ‘‘cured’’ at the posttranscriptional level by prevent-
ing the inclusion of specific mutant exons in the mature mRNA
and recovering a functional open reading frame (Aartsma-Rus
et al., 2009). The exon-skipping strategy allows the production
of a shorter but still functional dystrophin. This type of proteins
are found in Becker muscular dystrophy patients, who generally
show milder symptoms than do DMD patients.
Besides its well-defined structural role, the DAPC was shown
to influence the intracellular nitric oxide (NO) pathway: the disrup-
tion of the association between the sarcolemmal neuronal nitric
oxide synthase (nNOS) and DAPC leads to impaired NO produc-
tion indystrophicmuscles (Brenmanet al., 1995).NOhas recently
emerged as a key player which mediates epigenetic changes
through the direct control of histone deacetylases (HDACs). In
neurons, a NO-dependent S-nitrosylation of HDAC2 Cys resi-
dues (Cys262 and Cys274) induced the activation of genes for
neuronal development (Nott et al., 2008).Moreover, in the dystro-
phin-deficient mdx mice, defective for NO pathway, the activity
of HDAC2 resulted to be specifically increased (Colussi et al.,
2008).
The relevance of NO and HDAC2 activity in the Duchenne
pathology is supported by the evidence that rescue of nNOS
expression in mdx animals ameliorated the dystrophic pheno-
type (Wehling et al., 2001; Brunelli et al., 2007) and that deacety-
lase inhibitors conferred a strong morphofunctional benefit to
dystrophic muscle fibers (Minetti et al., 2006).
Recent works have shown that among genes which are
important for proper muscle development and function, micro-
RNAs (miRNAs) play a crucial role (Naguibneva et al., 2006;
Chen et al., 2006). Moreover, altered levels of miRNAs wereMetabolism 12, 341–351, October 6, 2010 ª2010 Elsevier Inc. 341
Figure 1. MicroRNA Expression in Duche-
nne Muscular Dystrophy
(A) Schematic representation of the exon-skipping
strategy for mdx mutation.
(B) Western blot with anti-dystrophin (DYS) and
anti-tubulin (TUB) antibodies performed on protein
extracts from the gastrocnemius of WT, mdx, and
AAV#23-treated mdx (G1, G2, and G3) animals,
sacrificed 4 weeks after systemic virus injection.
Dystrophin relative quantifications are shown on
the top of each lane.
(C) Histograms showmiRNA relative expression in
WT, G1-G3, and mdx mice, measured by qRT-
PCR.miR-23a andmiR-27awere used as controls.
Expression levels were normalized to snoRNA55
and shown with respect to WT set to a value of 1.
(D) Western blot with DYS and TUB antibodies on
protein extracts from human DMD myoblasts
infected with LV#51 (LV#51) or control (LV-mock)
lentiviruses and differentiated for 7 days.
(E) Histograms show miRNA relative expression in
LV-mock and LV#51-treated DMD cells measured
by qRT-PCR. U6 snRNAwas used as endogenous
control. Relative expressions are shown with
respect to LV-mock DMD cells, set to a value of
1. *p < 0.05, **p < 0.01.
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miRNA Players in DMD Pathogenesisfound in several muscular disorders such as myocardial infarc-
tion (van Rooij et al., 2008a), DMD, and other myopathies (Eisen-
berg et al., 2007; Greco et al., 2009).
In this work we took advantage of the exon-skipping strategy
to study whether the recovery of the dystrophin/nNOS pathway
correlated with the expression of miRNAs relevant for the DMD
physiopathology. We described that the activation of the NO
signaling modulates HDAC2 association with a specific subset
of miRNA genes and alteration of their expression correlates
with several pathogenetic traits of Duchenne disease.
RESULTS
The Expression Levels of Specific miRNAs Correlate
with the Amount of Dystrophin
Six-week-oldmdx animals were tail vein injected with a recombi-
nant adeno-associated viral vector carrying a U1-chimeric
antisense construct (AAV#23) previously reported to induce the
skipping of the mutated exon 23 and to restore dystrophin
synthesis (Figure 1A and Denti et al., 2006). After 1 month, mdx
and AAV#23-treated mdx siblings were sacrificed in parallel
with wild-type (WT) isogenic/aged matched animals. Different
muscular districts (gastrocnemius, diaphragm, triceps, and
quadriceps) were dissected and tissue collected for protein,
RNA, and chromatin analyses. Western blot revealed that
through the exon-skipping treatment, rescue of dystrophin was
obtained in all districts (data not shown), confirming the previ-
ously described body-wide activity of the AAV#23 virus. Due to
individual variability in the systemic delivery of AAV, we were
able to classify injected animals in three different groups (G1,
G2, and G3), which displayed %1%, 1%–5%, and 5%–10% of
dystrophin rescue, respectively. A representative sample of
each group is shown in Figure 1B.
Real-time based low density arrays revealed that the expres-
sion of a subset of miRNAs deregulated in mdx animals was342 Cell Metabolism 12, 341–351, October 6, 2010 ª2010 Elsevier Inrestored toward WT levels in AAV#23-treated mice (underlined
in Figure S1A and Table S1, available online).
Among the miRNAs analyzed by array, we validated by qRT-
PCR those showing themost prominent variations. Since homol-
ogous members of miR-29, miR-30, and miR-133 families were
equally deregulated, we focused our analysis on one member
per family. The muscle-specific (myomiR) miR-1 and miR-133
(van Rooij et al., 2008b) and the ubiquitous miR-29c and miR-
30c, downregulated in mdx, recovered toward WT levels in
exon-skipping-treated animals (Figure 1C). A direct correlation
between miRNA levels and dystrophin rescue was observed:
G1 animals showed a very limitedmiRNA recovery, while G3 dis-
played levels close to WT ones (Figure 1C).
At variance with the other myomiRs, miR-206 was highly
expressed inmdx aswell as in AAV#23-treated animals. Interest-
ingly, even if miR-206 was described on the same cluster with
miR-133b, suggesting that they may be transcribed together,
in mdx muscles miR-206 increases while miR-133b decreases.
Chromatin immunoprecipitation (ChIP) analysis for RNA poly-
merase II and histone-H3-lysine-9 acetylation (AcH3K9) (Fig-
ure S1D) and pri-miRNA quantifications (Figure S1E) in WT
versus mdx muscles indicated a higher transcriptional activity
on miR-206 coding region with respect to miR-133b, suggesting
that the two miRNAs are under an independent control.
The inflammatory miR-223 (Fazi et al., 2005), specific of granu-
locytic lineage, was found to be very abundant in mdx muscles
and proportionally reduced in the three groups of treated animals;
its decrease in AAV#23-mdx is consistent with the observed
ameliorationof the inflammatory stateof themuscledue todystro-
phin rescue (Denti et al., 2008; Aartsma-Rus et al., 2009). Finally,
theexpression levelsof theubiquitousmiR-23aandmiR-27awere
unchanged in WT andmdx, as well as in treated animals.
The relative changes in the expression patterns of miR-1,
miR-29, miR-206, and miR-223 observed in the gastrocnemius
were confirmed in other muscle districts (data not shown),c.
Figure 2. Dystrophin/nNOS Relocalization Modulates
HDAC2 Occupancy on miRNA Loci
(A) Gastrocnemius from WT, AAV#23-treated mdx, and control mdx
mice were analyzed by immunofluorescencewith DYS and nNOS anti-
bodies. Original magnification, 320. Scale bar, 100 mm.
(B) Protein extracts from the gastrocnemius of WT, AAV#23-treated
mdx (AAV#23) and control mdx, were immunoprecipitated with anti-
body against nitrosylated-Cys residues and assayed for HDAC2 by
western blot (nitroso-HDAC2). Below each lane the relative quantities
(RQ) with respect to WT are indicated. Values are normalized for the
amount of total HDAC2 (HDAC2) and represent the average of three
independent experiments.
(C and D) ChIP analyses performed onmiR-1-2/133a, miR-29b-2/29c,
andmiR-206 promoters (see schematic representation in Figure S2B).
(C) Histograms show RNA polymerase II (RNAPII), AcH3K9, and
HDAC2 enrichments in WT, AAV#23, and mdx gastrocnemius.
(D) Histograms show AcH3K9 and HDAC2 enrichments in control
(LV-mock) and antisense-treated (LV#51) DMD myoblasts. HPRT1
and tubulin (TUB) promoter regions were used as unrelated transcrip-
tional units, while 5.8S rRNA and tRNA genes were used as internal
negative controls (see representative gels in Figures S2C and S2D).
Results are expressed as fold enrichment of DNA-immunoprecipitated
samples relative to INPUT chromatin. *p < 0.05, **p < 0.01.
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miRNA Players in DMD Pathogenesisdemonstrating that the miRNA expression profile correlated
with dystrophin rescue in a body-wide manner. Moreover, injec-
tions of mdx mice with an AAV empty vector indicated that
virus adminstration per se did not affect miRNA expression
(Figure S1B).
The observation that the expression of a specific subset of
miRNAs varies in response to dystrophin prompted the analysis
in a human Duchenne model system. Differentiating DMD
myoblasts, carrying a deletion of exons 48–50, were treated
with a lentiviral construct expressing an antisense RNA able to
induce exon 51 skipping (LV#51) or with an empty vector
(LV-mock). This treatment was previously shown to produce an
in-frame mRNA and to rescue dystrophin synthesis (De Angelis
et al., 2002; Incitti et al., 2010). According to the mdx model,
when dystrophin synthesis was restored (Figure 1D), the levels
of miR-1, miR-133a, miR-29c, miR-30c, andmiR-206 increased,
while miR-23a expression did not change (Figure 1E).
HDAC2 Controls the Expression of Specific
miRNA Genes
Immunofluorescence analyses (Figure 2A) were performed with
anti-dystrophin and anti-nNOS antibodies on sections from the
gastrocnemius of WT, mdx, and G3 mdx (AAV#23). UponCell Metaboexon-skipping treatment, dystrophin synthesis and cor-
rect localization to the periphery of the fibers were
obtained (DYS); moreover, the restoration of dystrophin
paralleled the proper colocalization of nNOS to the
DAPC (nNOS). The morphological amelioration of the
muscles transduced with AAV#23 was also observed by
hematoxylin and eosin staining (Figure S2A).
One interesting target of nNOS was shown to be the
HDAC2 chromatin-remodeling enzyme (Nott et al., 2008;
Colussi et al., 2008). Therefore, we tested whether
HDAC2 was differentially nitrosylated in WT, mdx, and
AAV#23-treated mdx animals. Protein extracts were
immunoprecipitated with anti-nitrosocysteine antibodyand subsequently analyzed by western blot for HDAC2. The
lowest level of nitrosylated HDAC2 was found in mdx mice;
progressive increase of HDAC2 nitrosylation was detected in
AAV#23 and WT muscles (Figure 2B). These data provided
a correlation between nitrosylation state of HDAC2 and dystro-
phin levels.
Since the nitrosylation state of HDAC2 was found to affect its
association to the chromatin (Nott et al., 2008), we tested
whether altered levels of miRNAs in mdx were due to HDAC2
recruitment to their promoters. We selected the miR-1 and
miR-29 promoters, since they have been previously character-
ized (see Figure S2B and Rao et al., 2006; Liu et al., 2007;
Wang et al., 2008). ChIP analysis with antibodies against RNA
polymerase II (Lee et al., 2004) and AcH3K9 showed low binding
levels in mdx and progressive increase in G3 (AAV#23) and WT
animals (Figure 2C). These data indicated a good correlation
between the transcriptional state of these loci and the expres-
sion levels of the corresponding miRNAs (Figure 1C), confirming
that variations in miRNA expression depended on transcriptional
control. ChIP with anti-HDAC2 antibody revealed its specific
binding with miR-1 and miR-29 promoters only in mdx mice
(Figure 2C) where these miRNAs are downregulated. No reac-
tivity was observed with either HDAC1 or HDAC4. On thelism 12, 341–351, October 6, 2010 ª2010 Elsevier Inc. 343
Figure 3. NO Signaling Controls miRNA
Expression through HDAC2 Nitrosylation
(A–C) mice were injected with nitroglycerin (NTG)
into the right gastrocnemius andwith physiological
solution into the left one. After 4 hr, protein, RNA,
and chromatin samples were collected. (A, right
panel) Proteins were immunoprecipitated with
antibody against nitrosylated-Cys residues and
assayed for HDAC2 by western blot (nitroso-
HDAC2). Below each lane the relative quantities
(RQ) with respect to WT are indicated; values are
normalized for the amount of total HDAC2
(HDAC2) and represent the average of three inde-
pendent experiments. (B) Histograms show
miRNA relative expression measured by qRT-
PCR in NTG-treated (mdx NTG) or mock-injected
(mdx mock) mdx muscles with respect to WT one
set to a value of 1. Relative expressions were
normalized to snoRNA55. (C) ChIP analyses for
HDAC2 on miR-1-2/133a, miR-29b-2/29c, and
miR-206 promoters in WT, mdx NTG, and mdx
mock muscles. HPRT1 promoter region was
used as unrelated transcriptional unit while 5.8S
rDNA was used as an internal negative control.
Results are expressed as fold enrichment of DNA
immunoprecipitated samples relative to INPUT
chromatin.
(D–F)mdxmice were electroporated into the right tibialis with expression cassettes encoding for aWT flagged HDAC2 protein (Flag-HDAC2WT) or for a derivative
mutated at Cys262 and Cys274 (Flag-HDAC2mut). After 2 weeks mice were injected with NTG into the right tibialis and with physiological solution into the left one
(mock). After 4 hr protein, RNA and chromatin samples were collected. (D, right panel) Expression levels of flagged HDAC2 were assayed by western blot with
anti-Flag antibody (Flag-HDAC2). Nitrosylation state was revealed by immunoprecipitation with anti-Flag antibody followed by western blot using an antibody
against nitrosylated-Cys residues (nitroso-Flag-HDAC2). (E) Histograms show miRNA relative expression measured by qRT-PCR in mock-, Flag-HDAC2WT-,
and Flag-HDAC2mut-treated muscles. Expression levels were normalized to snoRNA55 and shown with respect to mock set to a value of 1. (F) ChIP analyses
were performed with anti-Flag antibody on miR-1-2/133a, miR-29b-2/29c, and miR-206 promoters in mock, Flag-HDAC2WT, and Flag-HDAC2mut treated
muscles. Results are expressed as fold enrichment of DNA immunoprecipitated samples relative to INPUT chromatin. **p < 0.01.
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miRNA Players in DMD Pathogenesiscontrary, the miR-206 promoter (characterized by M.C. and
D.C., unpublished data) did not reveal any HDAC2 interaction.
ChIP analyses were carried out also in human differentiating
DMD myoblasts infected with the lentiviral construct expressing
an antisense RNA (LV#51) able to rescue dytrophin synthesis.
The results indicated that also in this system the upregulation of
miR-1 and miR-29 correlated with release of HDAC2 from their
promoters and changes in histone acetylation state (Figure 2D).
Also in DMD cells no HDAC2 interaction was detected on miR-
206promoter. Thesedata indicate that both inmurine and human
dystrophic cells the absence of dystrophin correlates with
HDAC2 binding to a specific subset of miRNAs, while upon dys-
trophin rescue HDAC2 is released from these promoters.
Nitric Oxide Signaling Controls miRNA Expression
through HDAC2 Modification
Local injection of the NO-donor nitroglycerin (NTG) was utilized
as a way of inducing NO response to specific body districts.
Leg muscles ofmdx animals were injected with NTG, or physio-
logical solution as control, and dissected after 4 hr. Immunopre-
cipitation with antibody against nitrosylated cysteine residues
and subsequent HDAC2 western blot analysis indicated that
NTG treatment rescues the nitrosylated levels of HDAC2 to WT
values (Figure 3A). qRT-PCR and ChIP analysis were performed
to measure miRNA levels and HDAC2 association to the
corresponding promoters. The data show that NTG treatment
in mdx mice (1) increases miR-1 and miR-29 expression344 Cell Metabolism 12, 341–351, October 6, 2010 ª2010 Elsevier In(Figure 3B), (2) induces HDAC2 release from the promoters of
these miRNAs (Figure 3C), and (3) has no effect on miR-206.
To further prove the role of HDAC2 nitrosylation on miRNA
control, mdx muscles were electroporated with expression
cassettes encoding for a WT flagged-HDAC2 protein or for
a derivative mutated at the two cysteines (Cys 262 and Cys
274) known to be the target of nitrosylation (Nott et al., 2008).
Two weeks after treatment, NTG was locally injected and
samples extracted for protein, RNA, and chromatin analyses.
Figure 3D shows that both exogenous proteins are expressed
in the electroporated tissues (Flag-HDAC2) and only the WT
form can be nitrosylated (nitroso Flag-HDAC2). ChIP experi-
ments with anti-Flag antibodies showed that, upon NTG treat-
ment, WT Flag-HDAC2 was released from miR-1 and miR-29
promoters (Figure 3F), paralleling the increase of the correspond-
ingmiRNAs (Figure 3E); on the contrary, themutant Flag-HDAC2
protein remained bound to the promoters producing their down-
regulation (Figures 3E and 3F). No differences were observed on
the HDAC2-independent miR-206 promoter.
Altogether, these results demonstrate that NO induces
HDAC2 nitrosylation, thus regulating its binding on specific
miRNA promoters.
miR-206 Activates Satellite Cell Differentiation through
Pax7 Repression
The differential behavior of miR-1 andmiR-206 inWT versusmdx
prompted us to analyze inmore detail their pattern of expression.c.
Figure 4. miR-206 Expression and Function
(A) A miR-206 DIG-labeled probe was hybridized
on mdx and WT gastrocnemius sections. Original
magnification, 340. Scale bar, 50 mm.
(B) RNA and protein samples were extracted from
proliferating satellite cells (GM, growth medium)
and after shift to differentiation medium (DM) for
the indicated hours. (Upper panels) Northern blots
for miR-206, miR-1, and snoRNA55; (lower panels)
western blots for PAX7,myogenin (MYOG), dystro-
phin (DYS), and tubulin (TUB).
(C) Western blot for PAX7 on protein extracts of
murine satellite cells transfected with anti-miR-
206 or scramble LNA oligos in GM and switched
to DM for the indicated hours. Ponceau staining
was used as loading control.
(D) miR-1, miR-206, and U2 snRNA expression
analyzed by northern blot in C2 myoblasts main-
tained in GM or in DM for 5 days.
(E) ChIP analysis on miR-1-2/133a and miR-206
promoters with antibodies against AcH3K9,
HDAC2, and HDAC1 on chromatin from C2 cells
in GM and DM (see representative gels in
Figure S2E). 5.8S rDNA was used as internal nega-
tive control. Results are expressed as fold enrich-
ment of DNA immunoprecipitated samples relative
to INPUT chromatin. **p < 0.01.
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nucleotides in the 30 portion. In situ hybridization analysis was
performed onmdx and WT gastrocnemius by using DIG-labeled
probes. Signals for miR-206 were restricted to mdx and only in
immature regenerating fibers with centralized nuclei (Figure 4A),
whereas the miR-1 probe showed intense accumulation in
mature differentiated fibers in both WT and mdx fibers
(Figure S3A). Intact multinucleated fibers and small mononucle-
ated cells, such as inflammatory cells, fibroblasts, and prolifer-
ating satellite cells, lacked the miR-206 signals (note the
absence of signals in interstitial spaces where this type of cell
is visualized by DAPI staining in Figure S3A). Therefore,
increased expression of miR-206 inmdxmuscles is due to differ-
entiating satellite cells (Yuasa et al., 2008).
Next, we isolated mouse satellite cells from muscle biopses
and differentiated them in vitro (Rando and Blau, 1994). miR-
206 expression was activated at 12 hr, and its accumulation pro-
ceeded during differentiation (Figure 4B, upper panel). Notably,
the satellite-specifying factor Pax7 (Relaix et al., 2006), abundantCell Metabolism 12, 341–351in growth conditions, started to decrease
at 12 hr and completely disappeared at
24 hr, therefore showing an inverse corre-
lation with miR-206 levels (Figure 4B,
lower panel). Moreover, transfection of
in vitro-cultured satellite cells with anti-
miR-206 LNA oligonucleotides indicated
that in the absence of miR-206, Pax7
repression was unaffected at 12 hr and
remained detectable up to 48 hr
(Figure 4C and Figure S3B). The link
between Pax7 decrease, miR-206 induc-
tion, and the presence of miR-206 puta-tive target sites in the 30UTR of Pax7 mRNA led us to study
whether a regulatory interaction exists. Luciferase assays on
reporter constructs allowed us to validate the Pax7 30UTR as
a specific target of miR-206 (Figures S3C and S3D). These
experiments indicated that Pax7 can be repressed also by
miR-1; however, as shown in the Northern blot of Figure 4B, in
cultured satellite cells miR-1 is almost undetectable at 12 hr
when downregulation of Pax7 starts, allowing us to conclude
that mainly miR-206 is expressed at a time compatible with
Pax7 repression. Therefore, these data demonstrate that miR-
206 plays a specific role in early events of regeneration by re-
pressing the activity of Pax7, thus allowing the progression of
the differentiation program.
ChIP analysis for HDACs binding on the miR-1 and miR-206
loci in conditions of miRNA repression (GM, growth medium)
versus miRNA activation (DM, differentiation medium) in C2
myoblasts indicated that, differently from miR-1, miR-206 is
specifically repressed by HDAC1 (Figures 4D and 4E). The
restricted expression of miR-206 in early phases of, October 6, 2010 ª2010 Elsevier Inc. 345
Figure 5. miR-1 Controls G6PD Expression
(A) Total RNA and protein extracts, from C2 prolif-
erating myoblasts (GM, growth medium) and after
shift to differentiation medium (DM) for the indi-
cated hours. (Upper panels) Northern blot (miR-1
and U2 snRNA), (middle panels) western blot
(G6PD and HPRT1), (lower panel) GSH and
GSSG ratio obtained by enzymatic assay titration.
(B) Total RNA and protein extracts from WT, mdx,
and AAV#23-treatedmdx. (Upper panels) Northern
blot (miR-1 and snoRNA55), (middle panels)
western blot (G6PD and HPRT1), (lower panel)
GSH and GSSG ratio obtained by enzymatic assay
titration.
(C) (Upper panel) Protein extracts, from the
gastrocnemius of control mdx (mdx) and mdx
treated with G6PD (6-AN) or NOX (APO) inhibitors,
were immunoprecipitated with antibodies against
nitrosylated-Cys residues and analyzed for
HDAC2 content by western blot (nitroso-HDAC2).
On the top of each lane the relative quantities
(RQ) of nitroso-HDAC2 normalized for the amount
of total cellular HDAC2, with mdx set to a value of
1, are indicated. Values are the average of three
independent experiments. (Lower panel) qRT-
PCR for miR-1 on mdx, 6-AN, and APO mdx-
treated mice. Relative expressions were normal-
ized to snoRNA55 and shown with respect to
mdx set to a value of 1.
(D)mdx animals were electroporated with a miR-1 expression construct (p-miR-1) in the right gastrocnemius or with an empty vector (mock) in the controlateral
muscle and sacrificed after 25 days. miR-1, G6PD, and nitroso-HDAC2 levels were measured. Relative quantities (RQ), shown with respect tomdx set to a value
of 1, are indicated. The values are the average of three independent experiments. snoRNA55, ACTN, and HDAC2 were used for normalization.
(E) Pathway connecting G6PD, NOX, NO, HDAC2, and miR-1. **p < 0.01.
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miRNA Players in DMD Pathogenesisdifferentiation, before dystrophin synthesis starts, well correlates
with its expression being unaffected by the Dys/nNOS/HDAC2
pathway.
miR-1 Controls G6PD, a Relevant Enzyme
in the Response to Oxidative Stress
In silico analysis, performed by comparing mRNA expression
profiles in WT versusmdx animals (Tseng et al., 2002), identified
a large number of predicted targets of those miRNAs showing
the highest variations in our analysis. For the downregulated
miR-1, miR-29, andmiR-30, several upregulated targets relevant
in muscle physiology were found, such as those involved in ener-
getic metabolism, cytoskeleton remodeling, extracellular matrix,
and transcriptional regulation in muscle (Figure S4).
One important issue in dystrophic muscles is their suscepti-
bility and response to oxidative stress suggested to be involved
in disease progression (Rando et al., 1998). Glucose-6-phos-
phate dehydrogenase (G6PD) mRNA, deregulated in mdx
muscles, contains in its 30UTR three putative binding sites for
the miR-1 family (see Figure S5A).
G6PD is a cytosolic enzyme in the pentose phosphate
pathway that supplies reducing energy to cells by maintaining
the level of NADPH, which in turn ensures high ratio between
reduced and oxidized glutathione (GSH/GSSG), GSH being the
major antioxidant molecule that protects cells against oxidative
damage.
Luciferase reporter assays validated G6PD mRNA as a target
of the miR-1 family. Figure S5E shows that miR-1 and miR-206346 Cell Metabolism 12, 341–351, October 6, 2010 ª2010 Elsevier Inare able to repress luciferase activity only in the presence of
a WT G6PD-30UTR and that this repression is alleviated by
anti-miR-1 and anti-miR-206 LNA oligonucleotides.
Several data indicated an inverse correlation between G6PD
and miR-1 expression: in vitro differentiation of C2 myoblasts
showed that the increase inmiR-1 levels (Figure 5A, upper panel)
correlated with decrease of G6PD protein (Figure 5A, middle
panel), mRNA levels (Figure S5B), and GSH/GSSG ratio
(Figure 5A, lower panel). Figure 5B shows that in mdx mice,
where miR-1 is downregulated, G6PD was detected at higher
levels than in WT muscles, whereas in AAV#23-treated mdx, in
which miR-1 resumes, the amount of G6PD was reduced.
Notably, inmdxmice, increase in G6PD levels was accompanied
by a decrease in GSH/GSSG ratio (Figure 5B, lower panel). This
apparent contradiction can instead be explained considering
that in mdx muscles, most of the NADPH is utilized in the O2 to
O

2 conversion mediated by the Ca
2+-dependent activation of
NADPH oxidase (NOX; Shkryl et al., 2009). Detoxification of the
superoxide radical could further reduce NO levels already low
in mdx. Therefore, we asked whether interfering with this
pathway could affect the nitrosylation state of HDAC2. When
G6PD was inactivated through administration of 6-aminonicoti-
namide (6-AN; Walker et al., 1999), HDAC2 nitrosylation
increased as well as the levels of miR-1 (Figure 5C). In line with
this, NOX inhibition with apocynin (APO; Gupte et al., 2006)
also increased HDAC2 nitrosylation andmiR-1 levels (Figure 5C).
Finally, G6PD downregulation through overexpression of
miR-1 (p-miR-1) in mdx muscles increased HDAC2 nitrosylationc.
Figure 6. miR-29 Controls Fibrosis in mdx
(A) qRT-PCR for collagen (COL1A1) and elastin (ELN) mRNAs
performed on total RNA from the gastrocnemius of WT,
AAV#23-treated mdx, and mdx mice. Relative expressions
were normalized to HPRT1 and shown with respect to WT
set to a value of 1. In (B)–(E) the gastrocnemius ofmdx animals
was electroporated with a miR-29a/b expression construct
(p-miR-29) and sacrificed after 25 days in parallel with WT
and a control mdx electroporated with an empty plasmid
(mdx).
(B) PCR analysis on DNA from WT, mdx, and p-miR-29 elec-
troporated (1–4) mdx. Primers specific for the p-miR-29
construct and for the b-actin gene were utilized.
(C) Northern blot for miR-29 and control snoRNA55. Relative
quantities (RQ) of miR-29, relative to mdx set to a value of 1,
are indicated below each lane.
(D) qRT-PCR on COL1A1 and ELN mRNAs. Relative expres-
sions are normalized to HPRT1 mRNA. Values are shown
with respect to WT set to a value of 1.
(E) Masson’s trichrome staining indicates collagen deposition
(blue stain) on p-mock and p-miR-29 electroporated mdx.
Original magnification, 310. Scale bar, 100 mm. *p < 0.05,
**p < 0.01.
Cell Metabolism
miRNA Players in DMD Pathogenesiswith respect to control (Figure 5D). The link between G6PD, NO,
HDAC2, and miR-1 in mdx is shown in Figure 5E; namely, in
conditions of increased levels of G6PD more O

2 radicals,
deriving from the activity of NOX, are converted to ONOO
.
This reduced both NO levels and HDAC2 nitrosylation. Alto-
gether, these data demonstrate that all these components are
on the same pathway and that a feed-forward control between
G6PD and miR-1 through the S-nitrosylation of HDAC2 exists.
miR-29 Controls Fibrosis inmdxMuscles
mdx animals undergo extensive fibrotic degeneration (Haslett
et al., 2002). Crucial factors involved in this event are collagens
and elastin, structural components of the extracellular matrix,
whose mRNAs have been recently shown to be targeted by
miR-29 family in myocardial infarction (van Rooij et al., 2008a).
qRT-PCR revealed that in mdx, where miR-29 is poorly
expressed, the mRNAs for collagen (COL1A1) and elastin (ELN)
were upregulated. Their amount was instead reduced at levels
similar to WT in AAV#23-treated animals, where miR-29 levels
were resumed (Figure 6A). In order to test whether miR-29 aloneCell Metabolism 12is able to regulate collagen and elastin mRNAs in
the Duchenne fibrotic process, we electroporated
in the gastrocnemius of mdx animals a plasmid
DNA containing an expression cassette driving
the transcription of the miR-29a/b cluster (p-miR-
29). Control mdx mice were electroporated with
an empty plasmid. Twenty-five days after treat-
ment, muscles were dissected, and the presence
of p-miR-29 DNA was verified by PCR (Figure 6B).
Northern blot indicated that a 2- to 3-fold overex-
pression of miR-29 was specifically obtained
(Figure 6C) and that this paralleled a relevant
decrease of collagen and elastin mRNAs (Fig-
ure 6D). Trichromic staining on mdx mice electro-
porated with p-miR-29 indicated a strong decrease
in collagen deposition (blue stain) if compared tomock-electroporated muscles (Figure 6E). These data point to
miR-29 as a crucial player in the control of the extracellular
matrix modifications in mdx mice.
DISCUSSION
In DMD, muscle fiber breakage and degeneration, due to the
absence of dystrophin, are accompanied by a complex series
of events including activation of satellite cells, inflammatory infil-
tration, intense fibrosis, and oxidative stress. These pathoge-
netic features are ameliorated in mdx mice, in which dystrophin
is rescued through different therapeutic strategies (Aartsma-Rus
et al., 2009). Surprisingly, the beneficial effects observed on
muscle function and morphology could be obtained also with
low levels of protein (Denti et al., 2008; Ghahramani Seno
et al., 2008), suggesting that partial protein relocalization to the
membrane could be only part of the story. Dystrophin has
been suggested to affect gene expression through activation
of the NO pathway and HDAC2 regulation (Colussi et al.,
2009); however, no specific genes and regulatory circuitries, 341–351, October 6, 2010 ª2010 Elsevier Inc. 347
Figure 7. Model of the Pathway Connecting Dystrophin to Specific
miRNA Expression
(Left panel) InWTmuscle fibers the dystrophin/DAPC complex activates nNOS
and S-nitrosylation of HDAC2. The modified HDAC2 is released from the chro-
matin and activation of a specific subset ofmiRNA occurs. In DMD this circuitry
is deregulated due to impaired nNOS activity and decrease in HDAC2 nitrosy-
lation, causing its retention tomiRNA promoters. (Right panel) miR-206 follows
an independent control from the other myomiRs: it is controlled by HDAC1 and
expressed in activated satellite cells where it represses the Pax7 factor, thus
allowing differentiation to proceed.
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had been characterized. In this work, taking advantage of the
exon-skipping strategy, we identified a specific group ofmiRNAs
whose expression depends on dystrophin levels and whose
deregulation explains several DMD pathogenetic traits. This
class of miRNAs, poorly expressed in mdx, was upregulated
in exon-skipping-treated animals and included muscle spe-
cific (miR-1 and miR-133) and more ubiquitous (miR-29 and
miR-30) ones. The samemiRNAs displayed a dystrophin-depen-
dent upregulation also in human DMD myoblasts rescued for
dystrophin synthesis through exon skipping.
The transcriptional activation of these miRNAs correlated with
the acetylation state of H3K9 and modulation of HDAC2 binding
to their promoters: in the absence of dystrophin, the low miRNA
expression levels paralleled persistence of HDAC2 onto miRNA
regulatory regions. On the contrary, when dystrophin synthesis
was rescued, HDAC2 was released from miRNA promoters
and transcription resumed. The use of mutated HDAC2 as well
as treatment of mdx mice with NO donors indicated that the
release of HDAC2 from the chromatin was due to its nitrosyla-
tion. Notably, we showed that as a consequence of dystrophin
rescue, nNOS was stabilized and relocalized on the muscle
membrane, and this directly affected the nitrosylation levels of
HDAC2. Altogether, these data allowed us to conclude that dys-
trophin, nNOS, HDAC2 nitrosylation, and miRNAs are on the
same regulatory pathway as indicated in the model of Figure 7.
At variance with the other myomiRs, mainly present in mature
fibers, miR-206 was restricted to differentiating satellite cells;348 Cell Metabolism 12, 341–351, October 6, 2010 ª2010 Elsevier Intherefore, its higher levels in mdx and exon-skipping-treated
animals were due to massive regeneration occurring in dystro-
phic muscles. The compartmentalized expression observed
in vivo was confirmed in cultured satellite cells where miR-206
was shown to play the crucial function of repressing Pax7. This
transcriptional factor, which is the mark of myogenic progenitor
cells, has been described to regulate self-renewal of satellite
cells and their entry into the program of skeletal muscle differen-
tiation (Buckingham and Relaix, 2007).
Moreover, miR-206 differed from miR-1, also because it was
shown to be under the HDAC1 control. This, together with the
restricted expression in activated satellite cells before the onset
of dystrophin synthesis, is consistent with miR-206 being inde-
pendent from the Dys/nNOS pathway active in mature differen-
tiated fibers. These data disclose a different function for the
twomembers of themiR-1 family and provide amolecular mech-
anism for understanding how the switch between proliferation
and differentiation of satellite cells can be obtained.
The differential regulation of miR-1 and miR-206 also allows
us to suggest that the epigenetic control mediated by the late
differentiation marker, dystrophin, is very likely important for
increasing the robustness of the muscle differentiation program
consolidating only the expression of those miRNAs involved in
circuitries of terminal differentiation and tissue integrity.
Analysis of the targets of the modulated miRNAs underscored
regulatory networks important for understanding the DMD phys-
iopathology. One relevant discovery was the finding that miR-1
controls G6PD, a housekeeping enzyme encoded in mammals
by an X-linked gene. G6PD has important functions in interme-
diary metabolism because it catalyzes the first step in the
pentose phosphate pathway and provides reductive potential
in the form of NADPH; in fact, through NADPH production,
G6PD is required to maintain cytosolic GSH levels and to protect
against free radical injury. Disruption of the G6PD gene in male
mouse embryonic stem cells indicated that G6PD activity is
dispensable for pentose synthesis but is essential to protect
cells against even mild oxidative stress (Pandolfi et al., 1995).
At variance with normal muscles, in degenerating fibers most
of the NADPH produced is utilized in the O2 to O

2 conversion
mediated by the Ca2+-dependent activation of NOX (Gupte
et al., 2006; Shkryl et al., 2009), suggesting that in dystrophic
fibers G6PD may have an aberrant action in radical production.
Indeed, in mdx fibers higher expression levels of NOX were
detected (Shkryl et al., 2009), suggesting a major contribution
of this enzyme to the well-documented oxidative stress occur-
ring in these damaged muscles. Moreover, dystrophin-deficient
cells were shown to be more susceptible to free radical induced
injury when compared to normal cells, even though the two pop-
ulations were equally susceptible to other forms of metabolic
stress (Rando et al., 1998).
In line with these data, we demonstrated that while miR-1 was
able to downregulate G6PD, decreasing the levels of GSH in
normal muscles, in dystrophic ones the increase in G6PD did
not correlate with GSH levels. In mdx muscles, where the NOX
undergoes upregulation, most of the NO pool is utilized to
convert superoxide species (O

2) into peroxinitrite (ONOO
);
indeed, we show that under these conditions HDAC2 is
poorly nitrosylated, paralleling miR-1 repression and G6PD
upregulation.c.
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inhibition, had consequent effects both in increasing HDAC2
nitrosylation and miR-1 upregulation. Finally, local overexpres-
sion of miR-1 in mdx muscles determined downregulation of
G6PD and in turn increase of HDAC2 nitrosylation. Altogether,
these data proved the existence of a feed-forward circuitry
between G6PD and miR-1 through nitrosylation of HDAC2 (Fig-
ure 5E) and suggested that the regulatory network dependent
on the Dys/nNOS pathway has physiological relevance in
controlling also the oxidoreductase state of the injured muscle.
The relevant role of the identified dystrophin-dependent
miRNAs in the DMD pathogenesis was also tested for mir-29.
Its overexpression in the gastrocnemius of mdx animals indi-
cated that not only the target mRNAs for collagen and elastin
were specifically downregulated but also that the muscles
recovered a phenotype with a strong reduction in fibrosis.
It has been shown that a specific domain of dystrophin is
responsible for nNOS interaction (Wells et al., 2003; Lai et al.,
2009). Notably, this domain is absent in several Beker mutants
that produce a shorter but functional dystrophin; therefore, it
is likely that the dystrophin-nNOS pathway could only play
a consolidating function on muscle structure and that its mal-
functioning would be nonetheless compatible with life.
Altogether these findings show a link between the dystrophin/
nNOS pathway and important molecular circuitries, including
specific miRNAs and their targets, which play an important role
in muscle differentiation, homeostasis, and integrity. Moreover,
the identified epigenetic signature might provide a useful tool
for designing and monitoring the outcome of future clinical
studies as well as for identifying specific genes, correlated with
the DMD physiopathology, that might represent the basis for
new therapeutic interventions.
EXPERIMENTAL PROCEDURES
Animal Treatments and Constructs
Six-week-old mdx mice were tail vein injected with 0.5–1 3 1012 genome
copies of the AAV-U1#23 (AAV#23) or virus as described in Denti et al.
(2006) and sacrificed after 4 weeks. Electroporation was performed on
6-week-old mdx as described in Dona` et al. (2003). Plasmids carrying
miR-29a/b cluster (p-miR-29a), miR-1-2 (p-miR-1), and miR-206 (p-miR-206)
expression cassettes under the control of the U1snRNA promoter were utilized
(Fazi et al., 2005). WT and mutant FLAG-HDAC2 plasmids were provided by
Dr. A. Riccio and described in Nott et al. (2008). NTG treatments were per-
formed on 6- to 18-week-old mdx mice by local injections of 0.3 mg/kg of
NTG or physiological solution in tibialis or gastrocnemius muscles and sacri-
ficed after 4 hr. Apocynin and 6-aminonicotinamide were administered to
mdx mice by osmotic pumps (ALZET) as in Walker et al. (1999) and Gupte
et al. (2006).
Cell Culture
Muscle satellite cells were cultured and differentiated as described in Rando
and Blau (1994). The Duchenne primary myoblasts carrying exons 48–50
deletion were obtained from Telethon Biobank (Carlo Besta Institute, Milan)
and infected with a lentiviral construct containing antisense sequences against
the splice junctions of exon 51 (LV#51, Incitti et al., 2010). LNA miRNA Knock-
down (Exiqon) treatment was performed according to Taulli et al. (2009).
Protein and miRNA In Situ Analyses
Western blot on total extracts, H&E staining, and in situ analyses on 7 mm thick
gastrocnemius cryosections were performed as described in Denti et al.
(2006). In situ hybridizations were performed with NCL-DYS2 (Novocastra)
and nNOS (Santa Cruz). Immunoprecipitations on protein extracts were per-Cellformed with antibody against S-nitroso-Cys (Sigma) according to manufac-
turer’s specifications and revealed by western blot using an antibody against
HDAC2 (Upstate). Masson’s trichrome staining (Sigma) was performed
according to manufacturer’s specifications. miRNA in situ hybridization was
performed in formaldehyde and EDC-fixed gastrocnemius cryosections
according to Pena et al. (2009).
Chromatin Immunoprecipitation Assays
ChIP analysis was performed according to Ballarino et al., (2005) with the
following antibodies: HDAC2 and RNA Pol II (Santa Cruz), HDAC1, HDAC4,
acetylated H3-Lys9 (Upstate), and Flag (Sigma). The starting material was
1–3 mm3 for tissue samples or 1–10 3 105 cultured cells. ChIP assays on
DMD cells were performed using the EZ Magna ChIP Assay Kit (Millipore)
following the manufacturer’s specifications.
RNA procedures, enzymatic assays, and statistical analyses are available as
Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2010.07.008.
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